Current, there are no targeted therapies that are approved for the treatment of IgAN.

VIS649 is an investigational drug in clinical studies; its effectiveness and safety have not been established.

The enVision study: The main objectives are to evaluate the safety and tolerability of VIS649 and to evaluate the dose response of different doses of VIS649 by measuring proteinuria.

VIS649 is an investigational drug in clinical studies; its effectiveness and safety have not been established.